ENDRA Life Sciences Inc. Stock

Equities

NDRA

US29273B3024

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-04-15 pm EDT 5-day change 1st Jan Change
0.262 USD -29.19% Intraday chart for ENDRA Life Sciences Inc. -25.99% -87.64%
Sales 2024 * 1M Sales 2025 * - Capitalization 4.08M
Net income 2024 * -12M Net income 2025 * - EV / Sales 2024 * 4.08 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.26 x
P/E ratio 2025 *
-
Employees 21
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.85%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024
ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ENDRA Life Sciences Inc. Welcomes the Adoption of the ICD-10 K76.0 Code for the Diagnosis of Non-Alcoholic Fatty Liver Disease CI
Transcript : ENDRA Life Sciences Inc., Q3 2023 Earnings Call, Nov 14, 2023
ENDRA Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Top Premarket Decliners MT
Transcript : ENDRA Life Sciences Inc., H1 2023 Earnings Call, Aug 14, 2023
ENDRA Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
ENDRA Life Sciences Submits De Novo Request for its TAEUS System Liver Fat Application to the U.S. FDA CI
Certain Options of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023. CI
Certain Convertible Preferred Stock of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023. CI
Certain Warrants of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023. CI
Certain Common Stock of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023. CI
ENDRA Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : ENDRA Life Sciences Inc., Q1 2023 Earnings Call, May 15, 2023
More news
1 day-6.49%
1 week-0.48%
Current month-39.26%
1 month-64.77%
3 months-71.59%
6 months-66.45%
Current year-83.38%
More quotes
1 week
0.33
Extreme 0.3346
0.40
1 month
0.33
Extreme 0.3346
1.11
Current year
0.33
Extreme 0.3346
1.95
1 year
0.33
Extreme 0.3346
2.79
3 years
0.33
Extreme 0.3346
52.60
5 years
0.33
Extreme 0.3346
62.00
10 years
0.33
Extreme 0.3346
117.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 14-12-31
Director of Finance/CFO 38 21-06-17
Chief Tech/Sci/R&D Officer 55 06-12-31
Members of the board TitleAgeSince
Director/Board Member 56 13-06-30
Director/Board Member 62 07-12-31
Director/Board Member 69 14-12-31
More insiders
Date Price Change Volume
24-04-15 0.262 -29.19% 415,256
24-04-12 0.37 0.00% 65,087
24-04-11 0.37 +4.28% 239,509
24-04-10 0.3548 -1.50% 40,221
24-04-09 0.3602 +1.75% 150,311

Delayed Quote Nasdaq, April 15, 2024 at 11:02 am EDT

More quotes
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to an magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.37 USD
Average target price
11 USD
Spread / Average Target
+2,872.97%
Consensus